Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Display # 
Title Published Date
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 11 February 2016
Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology 15 January 2016
Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD 05 January 2016
300 million child-friendly antimalarial treatments supplied without profit by Novartis 09 December 2015
Novartis Foundation and partners launch new hypertension program in Ghana 29 October 2015
Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma 21 October 2015
Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases 15 October 2015
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years 08 October 2015
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries 28 September 2015
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist® 28 September 2015

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]